Compare Johnson & Johnson (JNJ) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Oxford Lane Capital Corp — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while Oxford Lane Capital Corp trades at $8.58 (market cap $835.71M). The key difference: Johnson & Johnson is far larger — about 739.6× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (28.15%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Oxford Lane Capital Corp for 50 Days on average.
| JNJ | OXLC | |
|---|---|---|
Market Cap | $618.09B | $835.71M |
Volume | 6,050,983 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $278.43 | $16.74 |
52-Week Low | $186.00 | $8.15 |
Typical Hold Time | 129 Days | 50 Days |
Enterprise Value | $646.37B | $1.23B |
Dividend Yield | 2.09% | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
OXLC trades at $8.655, up 2.3% today, but remains in a bearish technical trend with significant earnings volatility. The company reported a net loss of $585 million in 2026, missing EPS estimates for three consecutive quarters, while maintaining a high dividend payout. Analyst sentiment is mixed with a 50% buy rating, but technical indicators show strong selling pressure.
The outlook is cautious due to deteriorating fundamentals and high payout risks, though the stock trades below book value. Key risks include unsustainable dividends and NAV erosion, while potential upside hinges on CLO market recovery and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
